Compare Stocks → The attacks will come for me after releasing this… (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare ShareLink copied to clipboard. NASDAQ:ENTXNASDAQ:LIFENASDAQ:ONVONASDAQ:OTLK Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTXEntera Bio$2.07-0.5%$2.26$0.52▼$3.35$74.07M1.5984,084 shs44,825 shsLIFEaTyr Pharma$1.76$1.08▼$2.45$131.12M1.19514,103 shs269,400 shsONVOOrganovo$0.91-4.2%$1.01$0.85▼$2.05$13.02M0.68120,168 shs85,047 shsOTLKOutlook Therapeutics$7.67+0.1%$7.99$4.00▼$37.20$179.56M0.64222,619 shs113,168 shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTXEntera Bio-0.48%+3.50%-20.99%+51.09%+152.44%LIFEaTyr Pharma0.00%0.00%-0.78%-4.52%-14.03%ONVOOrganovo-4.65%-5.67%-12.06%-13.73%-53.31%OTLKOutlook Therapeutics+0.13%+12.96%+3.23%-6.92%-77.17%The attacks will come for me after releasing this… (Ad)America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTXEntera Bio1.9172 of 5 stars3.55.00.00.02.90.00.0LIFEaTyr Pharma3.1278 of 5 stars3.45.00.00.02.63.30.6ONVOOrganovo0.4983 of 5 stars0.05.00.00.02.80.00.6OTLKOutlook Therapeutics1.4654 of 5 stars3.42.00.00.01.81.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTXEntera Bio3.00Buy$10.00383.09% UpsideLIFEaTyr Pharma2.75Moderate Buy$23.67∞ UpsideONVOOrganovoN/AN/AN/AN/AOTLKOutlook Therapeutics2.88Moderate Buy$46.43505.28% UpsideCurrent Analyst RatingsLatest OTLK, ENTX, ONVO, and LIFE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2024ENTXEntera BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/17/2024OTLKOutlook TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.005/14/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.005/13/2024ENTXEntera BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/3/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.004/2/2024ENTXEntera BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/27/2024OTLKOutlook TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$50.003/25/2024OTLKOutlook TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.003/15/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.003/15/2024LIFEaTyr PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $16.00(Data available from 6/15/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTXEntera Bio$130K569.73N/AN/A$0.36 per share5.75LIFEaTyr Pharma$350K0.00N/AN/A$1.54 per share0.00ONVOOrganovo$110K118.33N/AN/A$0.36 per share2.52OTLKOutlook TherapeuticsN/AN/AN/AN/A($1.11) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTXEntera Bio-$8.89M-$0.28N/AN/AN/AN/A-103.40%-85.00%8/9/2024 (Estimated)LIFEaTyr Pharma-$50.39M-$0.90N/AN/AN/AN/A-56.92%-43.87%8/14/2024 (Estimated)ONVOOrganovo-$14.67M-$2.17N/AN/AN/AN/A-195.52%-142.62%7/11/2024 (Estimated)OTLKOutlook Therapeutics-$58.98M-$11.41N/AN/AN/AN/A-3,741.39%-167.29%8/12/2024 (Estimated)Latest OTLK, ENTX, ONVO, and LIFE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2024Q2 2024OTLKOutlook Therapeutics-$0.88-$1.55-$0.67$4.91N/AN/A5/10/2024Q1 2024ENTXEntera Bio-$0.06-$0.05+$0.01-$0.05N/AN/A5/2/2024Q1 2024LIFEaTyr Pharma-$0.24-$0.23+$0.01-$0.23$0.11 million$0.24 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTXEntera BioN/AN/AN/AN/AN/ALIFEaTyr PharmaN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTXEntera BioN/A8.708.70LIFEaTyr Pharma0.026.076.07ONVOOrganovoN/A2.121.96OTLKOutlook TherapeuticsN/A1.071.07OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTXEntera Bio14.11%LIFEaTyr Pharma61.72%ONVOOrganovo8.23%OTLKOutlook Therapeutics11.20%Insider OwnershipCompanyInsider OwnershipENTXEntera Bio8.90%LIFEaTyr Pharma3.70%ONVOOrganovo4.00%OTLKOutlook Therapeutics5.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableENTXEntera Bio1735.78 million32.60 millionOptionableLIFEaTyr Pharma5669.01 million66.46 millionOptionableONVOOrganovo1814.37 million13.80 millionOptionableOTLKOutlook Therapeutics2423.41 million22.17 millionOptionableOTLK, ENTX, ONVO, and LIFE HeadlinesRecent News About These CompaniesJune 15 at 3:40 AM | americanbankingnews.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Sees Large Increase in Short InterestJune 14 at 2:20 AM | americanbankingnews.comCritical Contrast: Outlook Therapeutics (NASDAQ:OTLK) vs. SOPHiA GENETICS (NASDAQ:SOPH)June 12 at 10:00 AM | accesswire.comOutlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell SeriesJune 11, 2024 | globenewswire.comOutlook Therapeutics® to Present at the Virtual Investor Pitch ConferenceJune 6, 2024 | accesswire.comOutlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC TeamJune 2, 2024 | marketbeat.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Rating of "Moderate Buy" from AnalystsMay 29, 2024 | interest.co.nzANZ Business Outlook survey: Confidence down - but so are inflation expectationsMay 29, 2024 | cnbcafrica.comChief Economists: The Economic Outlook Is Brightening But Political Risks Loom Large in 2024May 29, 2024 | finance.yahoo.comGlobal Sustainable Aviation Fuel (SAF) Market Outlook 2030 with Neste, World Energy, Gevo, Aemetis, and SkyNRG Dominating the $25 Billion IndustryMay 29, 2024 | markets.businessinsider.comBuy Rating Justified by Outlook Therapeutics’ Advancements and Market ProspectsMay 29, 2024 | bovnews.comIn the current cycle, Outlook Therapeutics Inc (OTLK) Stock is showing signs of growthMay 28, 2024 | msn.comOutlook gets EU approval for Lytenava for wet AMDMay 28, 2024 | globenewswire.comOutlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDMay 28, 2024 | phonearena.comMicrosoft adds major new feature to Outlook Lite on AndroidMay 28, 2024 | indiaeducationdiary.inIndian meteorological Department (IMD) updated Long Range Forecast Outlook for the Southwest Monsoon Rainfall Season (June-September)2024May 28, 2024 | heise.deNew Outlook: Return to classic Outlook to be less simpleMay 22, 2024 | marketbeat.comChardan Capital Weighs in on Outlook Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:OTLK)May 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Outlook Therapeutics on Strong EU Prospects and Solid Financial PositionMay 17, 2024 | marketbeat.comOutlook Therapeutics (NASDAQ:OTLK) Given "Buy" Rating at HC WainwrightMay 17, 2024 | msn.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Q2 2024 Earnings Call TranscriptMay 17, 2024 | finance.yahoo.comQ2 2024 Outlook Therapeutics Inc Earnings CallNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEntera BioNASDAQ:ENTXEntera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.aTyr PharmaNASDAQ:LIFEaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.OrganovoNASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.Outlook TherapeuticsNASDAQ:OTLKOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.